Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

A Daddy’s heart is healthier: Study

A new study shows that fathers are less likely to die of heart disease than men who’ve never had kids. This raises questions about a possible biological link between male infertility and overall health. Other recent studies have found a connection between testicular and prostate cancer and infertility.

27 Sep 2011

Low vitamin B12 raises risk of dementia in the elderly: Study

According to a latest study the elderly with low levels of vitamin B12 in their blood may be more likely to develop problems with their thinking skills and have more brain shrinkage. The study points to a link between low B12 and early cognitive decline, a condition that often leads to dementia. Previous research has found that those people with high levels of vitamin B12 in their blood have lower levels of an amino acid called homocysteine, which some studies have linked to an increased risk of Alzheimer's disease, memory loss, and stroke.

27 Sep 2011

WPI professor receives AHA fellowship for research into cardiovascular disease

Dalin Tang, professor of mathematical sciences and biomedical engineering at Worcester Polytechnic Institute (WPI), has been elected a fellow of the American Heart Association (AHA). Tang was elected to fellowship by the AHA's Council on Basic Cardiovascular Sciences in recognition of his "major and productive contributions in cardiovascular basic science."

27 Sep 2011

HCRI completes enrollment in dual antiplatelet therapy clinical trial

The Harvard Clinical Research Institute (HCRI) announced today that the enrollment phase of the DAPT Study has been successfully completed. The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

27 Sep 2011

$Women ages 65-69 with hip fracture more likely to die within a year$

Women ages 65-69 with hip fracture more likely to die within a year

Women ages 65-69 who break a hip are five times more likely to die within a year than women of the same age who don't break a hip, according to a Kaiser Permanente Center for Health Research study funded by the National Institutes of Health and published online today in the Archives of Internal Medicine.

27 Sep 2011

Eating blueberries may inhibit breast cancer tumor growth

Eating blueberries may inhibit breast cancer tumor growth, according to a recent study by researchers at the City of Hope in Los Angeles that is published in the October 2011 issue of The Journal Of Nutrition and featured in the September issue of Food Nutrition & Science.

27 Sep 2011

Vitamin B12 deficiency linked to cognitive problems or loss in brain volume among older people

Older people with low levels of vitamin B12 in their blood may be more likely to lose brain cells and develop problems with their thinking skills, according to a study published in the September 27, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

27 Sep 2011

Men over 75 with prostate cancer are being undertreated: Study

It's an ongoing debate: Should men over a certain age be treated for prostate cancer? Should these patients be submitted to treatments that may result in significant side effects if they may not live very much longer?

27 Sep 2011

People with COPD, reduced lung function more likely to develop cardiovascular disease

A new study has shown that people with chronic obstructive pulmonary disease (COPD) or people with reduced lung function are at a serious risk of developing cardiovascular disease.

26 Sep 2011

New insights into actions of NSAIDs

Ibuprofen, naproxen, and related non-steroidal anti-inflammatory drugs (NSAIDs) - the subjects of years of study - still have some secrets to reveal about how they work.

26 Sep 2011

JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME

iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

NINDS award to fund studies of Arizonans with Parkinson's disease

The National Institute of Neurological Disorders and Stroke (NINDS) announced this week an $8 million, five-year grant to support a "National Brain and Tissue Resource for Parkinson's Disease and Related Disorders", awarded to Banner Sun Health Research Institute (BSHRI) and Mayo Clinic Arizona.

26 Sep 2011

University of Utah develops video game to help children with cancer

Even super heroes need a chance to get better, especially if they've been fighting their arch-nemesis and a robotic crab that just won't go away. At least, that's the premise behind a video game developed at the University of Utah to help children with cancer during their treatment.

26 Sep 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

Six ways to prevent coronary artery disease

In honor of National Cholesterol Education Month, Hotze Health & Wellness Center (HHWC) is encouraging both men and women to take a proactive role in healthy aging, specifically heart disease prevention. HHWC is advocating effective measures to prevent heart attacks and is shedding new light on cholesterol myths and the dangers of cholesterol-lowering (statin) drugs.

23 Sep 2011

Soy protein reduces progression of atherosclerosis in women within 5 years of menopause

A new study published in the November 2011 issue of Stroke reveals some promising data on the positive effects of soy protein reducing the progression of clogged arteries in women who were within five years of menopause. This study was the largest and longest randomized controlled human study conducted to-date that directly investigated the efficacy of isolated soy protein consumption on the progression of atherosclerosis.

23 Sep 2011

AHA certifies walnuts as heart-healthy food

California Walnuts is proud to announce that the American Heart Association is now certifying walnuts as a heart-healthy food. The Heart-Check mark easily identifies foods that meet the nutritional standards set by the American Heart Association and provides consumers a quick and reliable way to identify heart-healthy foods.

23 Sep 2011

USPTO issues patent for Lixte's LB-100 to treat cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity.

23 Sep 2011